Switch theme
Sign up to access all valuation multiples
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
2020
573
LTM Revenue $11.9M
LTM EBITDA $12K
$86.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LakeShore Biopharma Co has a last 12-month revenue (LTM) of $11.9M and a last 12-month EBITDA of $12K.
In the most recent fiscal year, LakeShore Biopharma Co achieved revenue of $615M and an EBITDA of -$48.5M.
LakeShore Biopharma Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LakeShore Biopharma Co valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11.9M | XXX | $615M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $507M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $12K | XXX | -$48.5M | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | -8% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$44.5M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -7% | XXX | XXX | XXX |
| Net Profit | -$1.9M | XXX | -$100.0M | XXX | XXX | XXX |
| Net Margin | -16% | XXX | -16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $386M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, LakeShore Biopharma Co's stock price is $1.
LakeShore Biopharma Co has current market cap of $32.1M, and EV of $86.0M.
See LakeShore Biopharma Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $86.0M | $32.1M | XXX | XXX | XXX | XXX | $-0.73 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, LakeShore Biopharma Co has market cap of $32.1M and EV of $86.0M.
LakeShore Biopharma Co's trades at 0.1x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate LakeShore Biopharma Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LakeShore Biopharma Co has a P/E ratio of -2.3x.
See valuation multiples for LakeShore Biopharma Co and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.1M | XXX | $32.1M | XXX | XXX | XXX |
| EV (current) | $86.0M | XXX | $86.0M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | 978.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.3x | XXX | -0.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLakeShore Biopharma Co's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.0M for the same period.
LakeShore Biopharma Co's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LakeShore Biopharma Co's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for LakeShore Biopharma Co and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | -21% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 90% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LakeShore Biopharma Co acquired XXX companies to date.
Last acquisition by LakeShore Biopharma Co was XXXXXXXX, XXXXX XXXXX XXXXXX . LakeShore Biopharma Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was LakeShore Biopharma Co founded? | LakeShore Biopharma Co was founded in 2020. |
| Where is LakeShore Biopharma Co headquartered? | LakeShore Biopharma Co is headquartered in United States of America. |
| How many employees does LakeShore Biopharma Co have? | As of today, LakeShore Biopharma Co has 573 employees. |
| Who is the CEO of LakeShore Biopharma Co? | LakeShore Biopharma Co's CEO is Mr. Xu Wang. |
| Is LakeShore Biopharma Co publicy listed? | Yes, LakeShore Biopharma Co is a public company listed on NAS. |
| What is the stock symbol of LakeShore Biopharma Co? | LakeShore Biopharma Co trades under LSB ticker. |
| When did LakeShore Biopharma Co go public? | LakeShore Biopharma Co went public in 2023. |
| Who are competitors of LakeShore Biopharma Co? | Similar companies to LakeShore Biopharma Co include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of LakeShore Biopharma Co? | LakeShore Biopharma Co's current market cap is $32.1M |
| What is the current revenue of LakeShore Biopharma Co? | LakeShore Biopharma Co's last 12 months revenue is $11.9M. |
| What is the current EV/Revenue multiple of LakeShore Biopharma Co? | Current revenue multiple of LakeShore Biopharma Co is 1.0x. |
| Is LakeShore Biopharma Co profitable? | Yes, LakeShore Biopharma Co is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of LakeShore Biopharma Co? | LakeShore Biopharma Co's last 12 months EBITDA is $12K. |
| What is LakeShore Biopharma Co's EBITDA margin? | LakeShore Biopharma Co's last 12 months EBITDA margin is 0%. |
| What is the current EV/EBITDA multiple of LakeShore Biopharma Co? | Current EBITDA multiple of LakeShore Biopharma Co is 978.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
